At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 375 enrolled
Drug / intervention
Rotarix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.
In Brief
A Phase 2 clinical trial evaluating Rotarix™ and Placebo for Infections, Rotavirus and Rotavirus Vaccines. Completed, enrolled 375 participants across 1 site.
Detailed Summary
This study will provide data on the immune response and safety of GSK Biologicals' HRV liquid vaccine when given along with the routine infant immunizations in Philippines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Rotavirus, Rotavirus Vaccines
CountriesPhilippines
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartMar 2007
Primary CompletionSep 2007
TodayJul 2026
First PostedFeb 7, 2007
Enrollment StartMar 9, 2007
Primary CompletionSep 4, 2007
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.4 years ago
Interventions
Rotarix™biological
oral doses
Placebobiological
oral dose